| Abstract |
Objective: Based on the repetitive set of neuropsychological state tests, the characteristics of cognitive function before and after treatment of new antidepressant drugs in patients with first-episode and recurrent depressive disorder, and their relationship with clinical features and severity of symptoms. Methods: 46 patients with first-episode depressive disorder, 42 patients with recurrent depressive disorder, and 39 normal controls were enrolled. The Hamilton Depression Scale (HAMD-24) was used to assess the severity of depression, and the patients recognition was assessed with the repeatable battery for the assessment of neuropsychological status. Results: ① There were significant differences in the memory, speech function, attention, time-lapse memory and RBANS total scores between the first group, the recurrent group and the normal control group ( P < 0.05). Pairwise analysis found that the total scores of RBANS and RBANS in the first and second groups were lower than those in the normal control group, and the difference was statistically significant ( P<0.05). The total scores of the five factors and RBANS in the first group were higher than those in the recurrence group. The immediate memory, speech function, attention, time delay memory and RBANS total scores were statistically significant between the two groups (P<0.05)Conclusions. ② There were significant differences in immediate memory, attention, time-lapse memory and RBANS total scores between the first and recurrent groups after 8 weeks of treatment and the normal control group ( P<0.05). In the first-episode group and the recurrent group, the immediate memory, delayed memory, and total RBANS scores were lower than those in the normal control group, with significant differences (P<0.05).And the attention factor in the recurrent group was significantly lower than that in the normal control group (P<0.05). In addtion the total scores of the five factors and RBANS in the first group were higher than those in the recurrent group. The visual extent, delayed memory, and total RBANS scores were statistically significant between the two groups ( P<0.05). ③ Before and after treatment, patients with primary and recurrent depressive disorder had significant changes in HAMA total score, HAMD total score, RBANS scores and RBANS total scores. The difference was statistically significant ( P < 0.05). ④ The HAMD partial factor score and the HAMD total score are negatively related to the RBANS partial factor score and the RBANS total score ( P<0.05). Conclusion: Patients with first-episode and recurrent depressive disorders not only have emotional symptoms, but also have extensive cognitive impairment,and recurrent patients have more severe cognitive dysfunction than first-person patients. New antidepressants can effectively alleviate depressive symptoms and can Partially improve the cognitive function of patients. Cognitive impairment of depressive disorder is associated with severity of symptoms.
|